Image

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Studying Ziftomenib combinations for relapsed/refractory acute myeloid leukemia.

Recruiting
18 years and older
All
Phase 1
  • Simplified description (AI rewritten)
  • Technical description (Original)

This study looks at how safe and tolerable the drug ziftomenib is when combined with regular treatments for people with a type of blood cancer called acute myeloid leukemia (AML). People in this study have a specific kind of AML that has come back or didn't get better with other treatments. The study will test ziftomenib with other drugs: FLAG-IDA (a mix of fludarabine, cytarabine, and idarubicin), low-dose cytarabine, and gilteritinib.

  • Participants need to have specific genetic changes like NPM1 mutation or KMT2A rearrangement.
  • There are several medical requirements, such as having good liver and kidney function.
  • Participants cannot join if they have certain other types of leukemia or active infections.

Being part of a study like this can help doctors learn more about treating AML, but it may also come with some risks. Participants should discuss with their doctors to understand if this study is a good fit for them.

Print
Study details
    AML
    AML With Mutated NPM1
    Hematologic Malignancy
    KMT2Ar
    NPM1 Mutation
    MLL Rearrangement
    Leukemia
    Acute Myeloid Leukemia
    Leukemia
    Myeloid
    Leukemia
    Myeloid
    Acute
    Acute Leukemia
    Neoplasms by Histologic Type

NCT06001788

Kura Oncology, Inc.

7 March 2026

Contact a study center
Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Race
Ethnicity
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.